CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 414 filers reported holding CRISPR THERAPEUTICS AG in Q4 2020. The put-call ratio across all filers is 1.10 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $219,000 | +7.4% | 3,351 | 0.0% | 0.01% | +20.0% |
| Q2 2022 | $204,000 | -2.9% | 3,351 | 0.0% | 0.01% | +25.0% |
| Q1 2022 | $210,000 | +1.0% | 3,351 | +21.8% | 0.00% | 0.0% |
| Q4 2021 | $208,000 | -28.3% | 2,751 | +6.2% | 0.00% | -42.9% |
| Q3 2021 | $290,000 | -30.6% | 2,591 | +0.4% | 0.01% | -30.0% |
| Q2 2021 | $418,000 | +39.3% | 2,581 | +4.9% | 0.01% | +25.0% |
| Q1 2021 | $300,000 | -20.0% | 2,461 | +0.4% | 0.01% | -20.0% |
| Q4 2020 | $375,000 | -10.7% | 2,450 | -74.1% | 0.01% | -28.6% |
| Q3 2018 | $420,000 | +52.2% | 9,460 | -19.6% | 0.01% | +40.0% |
| Q4 2017 | $276,000 | – | 11,765 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 498,558 | $27,989,046 | 33.20% |
| Gilfoyle Management LLC | 100 | $4,842 | 15.90% |
| NEA Management Company, LLC | 1,587,854 | $89,142,124 | 6.80% |
| ARK Investment Management | 7,338,447 | $411,980,394 | 2.73% |
| Nikko Asset Management Americas, Inc. | 3,533,357 | $198,327,328 | 2.09% |
| Del-Sette Capital Management, LLC | 33,661 | $1,889,729 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Ikarian Capital, LLC | 200,000 | $11,228,000 | 1.79% |
| Merlin Capital, Inc | 8,802 | $494,144 | 1.67% |
| Green Alpha Advisors, LLC | 34,373 | $1,929,700 | 1.27% |